contactenos@vnovamed.com.co

AZEFLU®

REG. SAN. NO. INVIMA:
INVIMA 2018M-0018440

PRINCIPIO ACTIVO:
Azelastina Clorhidrato 137 mcg-Fluticasona Propionato 50 mcg.

UNIDAD DE VENTA:
Suspencion Spray Nasal.

Mas Información

Bibliografía Referencias:

  1. Berger WE, Mustakov TB, Kralimarkova TZ, Christoff G, Popov TA. Treatment with azelastine hydrochloride and fluticasone propionate in a single delivery device of young children and adolescents with allergic rhinitis. Allergy Asthma Proc. 2020.
  2. Bousquet J, Van Cauwenberge P, Khaltaev NAria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001.
  3. Kremer B, den Hartog HM, Jolles J. Relationship between allergic rhinitis, disturbed cognitive functions and psychological well-being. Clin Exp Allergy. 2002.
  4. Mastrorilli C, Posa D, Cipriani F, Caffarelli C. Asthma and allergic rhinitis in childhood: what’s new. Pediatr Allergy Immunol. 2016.
  5. Santos AF, Borrego LM, Rotiroti G, Scadding G, Roberts G. The need for patient-focused therapy for children and teenagers with allergic rhinitis: a case-based review of current European practice. Clin Transl Allergy. 2015.
  6. Poddighe D, Gelardi M, Licari A, Del Giudice MM, Marseglia GL. Non-allergic rhinitis in children: epidemiological aspects, pathological features, diagnostic methodology and clinical management. World J Methodol. 2016; 6:200–213.
  7. Cheng X, Sheng H, Ma R, Gao Z, Han Z, Chi F, et al. Allergic rhinitis and allergy are risk factors for otitis media with effusion: a meta-analysis. Allergol Immunopathol (Madr). 2017.
  8. Ibáñez MD, Valero AL, Montoro J, Jauregui I, Ferrer M, Dávila I, et al. Analysis of comorbidities and therapeutic approach for allergic rhinitis in a pediatric population in Spain. Pediatr Allergy Immunol. 2013.
  9. Brew BK, Lundholm C, Gong T, Larsson H, Almqvist C. The familial aggregation of atopic diseases and depression or anxiety in children. Clin Exp Allergy. 2018.
  10. Fitzsimons R, van der Poel LA, Thornhill W, du Toit G, Shah N, Brough HA. Antihistamine use in children. Arch Dis Child Educ Pract Ed. 2015.
  11. Roberts G, Xatzipsalti M, Borrego LM, Custovic A, Halken S, Hellings PW, et al. Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy. 2013.
  12. Jáuregui I, Dávila I, Sastre J, Bartra J, del Cuvillo A, Ferrer M, et al. Validation of ARIA (Allergic Rhinitis and its Impact on Asthma) classification in a pediatric population: the PEDRIAL study. Pediatr Allergy Immunol. 2011.
  13. Carr WW, Yawn BP. Management of allergic rhinitis in the era of effective over-the-counter treatments. Postgrad Med. 2017.
  14. Horak F, Zieglmayer UP. Azelastine nasal spray for the treatment of allergic and nonallergic rhinitis. Expert Rev Clin Immunol. 2009.
  15. Ellis AK, Zhu Y, Steacy LM, Walker T, Day JH. A four-way, double-blind, randomized, placebo controlled study to determine the efficacy and speed of azelastine nasal spray, versus loratadine, and cetirizine in adult subjects with allergen-induced seasonal allergic rhinitis. Allergy Asthma Clin Immunol. 2013.
  16. Corren J, Storms W, Bernstein J, Berger W, Nayak A, Sacks H, et al. Effectiveness of azelastine nasal spray compared with oral cetirizine in patients with seasonal allergic rhinitis. Clin Ther. 2005.
  17. Sastre J, Mosges R. Local and systemic safety of intranasal corticosteroids. J Investig Allergol Clin Immunol. 2012.
  18. Derendorf H, Munzel U, Petzold U, Maus J, Mascher H, Hermann R, et al. Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. Br J Clin Pharmacol. 2012.
  19. Di Lorenzo G, Pacor ML, Pellitteri ME, Morici G, Di Gregoli A, Lo Bianco C, et al. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy. 2004.
  20. Watts AM, Cripps AW, West NP, Cox AJ. Modulation of allergic inflammation in the nasal mucosa of allergic rhinitis sufferers with topical pharmaceutical agents. Front Pharmacol. 2019.
  21. Carr W, Bernstein J, Lieberman P, Meltzer E, Bachert C, Price D, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol.2012; 129:1282–1289.e10.
  22. Bernstein JA. MP29-02: a breakthrough for the treatment of allergic rhinitis. Expert Opin Pharmacother. 2013; 14:2101–2113.
  23. Berger WE. MP29-02 for the treatment of seasonal allergic rhinitis: a review of clinical pharmacology, efficacy and safety. Expert Rev Clin Immunol. 2013; 9:803–811.
  24. Derendorf H, Meltzer EO, Hermann R, Canonica GW. Clinical development of an advanced intranasal delivery system of azelastine hydrochloride and fluticasone propionate. Drugs Today (Barc), 2014; 50:15–31.
  25. Klimek L, Bousquet J, Price D. Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitis. Expert Opin Drug Saf. 2016; 15:117–129.
  26. Bousquet J, Bachert C, Bernstein J, Canonica GW, Carr W, Dahl R, et al. Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps. Expert Opin Pharmacother. 2015; 16:913–928.
  27. Klimek L, Bachert C, Stjärne P, Dollner R, Larsen P, Haahr P, et al. AzeFlu provides rapid and effective allergic rinitis control in real life: a pan-European study. Allergy Asthma Proc. 2016; 37:376–386.
  28. Berger WE, Shah S, Lieberman P, Hadley J, Price D, Munzel U, et al. Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis. J Allergy Clin Immunol Pract. 2014; 2:179–185.
  29. Scadding G, Price D, El-Shanawany T, Ahmed S, Ray J, Sargur R, et al. Multicentre, non-interventional study to assess the profile of patients with uncontrolled rhinitis prescribed a novel formulation of azelastine hydrochloride and fluticasone propionate in a single spray in routine clinical practice in the UK. BMJ Open. 2017; 7:e014777
  30. Berger W, Meltzer EO, Amar N, Fox AT, Just J, Muraro A, et al. Efficacy of AzeFlu in children with seasonal allergic rhinitis: importance of paediatric symptom assessment. Pediatr Allergy Immunol. 2016; 27:126–133.
  31. Berger W, Bousquet J, Fox AT, Just J, Muraro A, Nieto A, et al. AzeFlu is more effective than fluticasone propionate for the treatment of allergic rhinitis in children. Allergy. 2016; 71:1219–1222.
  32. Berger W, Sher E, Gawchik S, Fineman S. Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: a randomized clinical trial. Allergy Asthma Proc. 2018; 39:110–116.
  33. Price D, Shah S, Bhatia S, Bachert C, Berger W, Bousquet J, et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. J Investig Allergol Clin Immunol. 2013; 23:495–503.
  34. Hampel FC, Ratner PH, Van Bavel J, Amar NJ, Daftary P, Wheeler W, et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol. 2010; 105:168–173.
  35. Meltzer E, Ratner P, Bachert C, Carr W, Berger W, Canonica GW, et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol. 2013; 161:369–377.
  36. Klimek L, Bachert C, Mösges R, Munzel U, Price D, Virchow JC, et al. Effectiveness of MP29-02 for the treatment of allergic rinitis in real-life: results from a noninterventional study. Allergy Asthma Proc. 2015; 36:40–47.
  37. Haahr PA, Jacobsen C, Christensen ME. AzeFlu provides rapid and effective allergic rhinitis control: results of a noninterventional study in Denmark. Int Forum Allergy Rhinol. 2019; 9:388–395.
  38. Stjarne P, Strand V, Theman K, Ehnhage A. Control of allergic rhinitis with AzeFlu: a non interventional study of a Swedish cohort. Rhinology. 2019; 57:279–286.